Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double Blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)

NCT02156063 is registered in ClinicalTrials.gov with Nora Therapeutics, Inc. as lead sponsor.

NCT NCT02156063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02156063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double Blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)
Lead sponsor
Nora Therapeutics, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2014
Completion date
June 30, 2016
Enrollment
150 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent miscarriage, recurrent pregnancy loss